[Immunotherapies - Overview, mode of action and clinical implications].

Bill, Ruben; Schardt, Julian (2019). [Immunotherapies - Overview, mode of action and clinical implications]. Therapeutische Umschau, 76(4), pp. 187-194. Hogrefe 10.1024/0040-5930/a001083

[img] Text
Immuntherapie.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (871kB)

Immunotherapies - Overview, mode of action and clinical implications Abstract. The introduction of immunotherapies has led to major advances in the treatment of cancer patients. The mainstays of immunotherapies in clinical routine are immune checkpoint inhibitors. Immune checkpoints like CTLA-4 or the PD-1 / PD-L1 axis are important contributors to the immune homeostasis by preventing overshooting immune responses against pathogens and thus preventing collateral damage to normal tissue, or by preventing autoimmunity. However, immune checkpoints can impede the development of an efficient anti-tumor immune response. Thus, therapeutic monoclonal antibodies against CTLA-4 and PD-1 or PD-L1 displayed remarkable clinical activity such as complete sustained clinical remission even in patients bearing multiple metastases. Malignant melanoma, non-small cell lung cancer or Hodgkin's lymphoma are examples of cancer entities with especially well clinical responses to immune checkpoint inhibitors. This fast-developing field is rapidly expanding the indications for immune checkpoint inhibitors and combinations with other therapeutic strategies like vessel-modulating agents or classical chemotherapy are in preclinical and clinical testing. In this article, the mechanistic principles of immune checkpoint inhibition and their clinical applications are illustrated.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Bill, Ruben, Schardt, Julian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0040-5930

Publisher:

Hogrefe

Language:

German

Submitter:

Rebeka Gerber

Date Deposited:

05 Nov 2019 08:39

Last Modified:

05 Dec 2022 15:31

Publisher DOI:

10.1024/0040-5930/a001083

PubMed ID:

31498037

BORIS DOI:

10.7892/boris.134313

URI:

https://boris.unibe.ch/id/eprint/134313

Actions (login required)

Edit item Edit item
Provide Feedback